Abstract
BackgroundMetaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between metaplastic breast cancer and triple-negative breast cancer in the era of third-generation chemotherapy remain unclear.MethodsWe compared the clinical outcomes between women with metaplastic breast cancer and women with triple-negative breast cancer diagnosed between 1994 and 2014. Metaplastic breast cancer patients were matched 1:3 to triple-negative breast cancer patients by stage and age at diagnosis. Distant disease-free survival (DDFS) and overall survival (OS) were estimated using Kaplan Meier methods and Cox proportional hazard regression models. Immune checkpoint markers were characterized by immunohistochemistry in a subset of samples.ResultsForty-four metaplastic breast cancer patients (stage I 14%; stage II 73%; stage III 11%; stage IV 2%) with an average age of 55.4 (± 13.9) years at diagnosis. Median follow-up for the included metaplastic breast cancer and triple-negative breast cancer patients (n = 174) was 2.8 (0.1–19.0) years. The DDFS and OS between matched metaplastic breast cancer and triple-negative breast cancer patients were similar, even when adjusting for clinical covariates (DDFS: HR = 1.64, p = 0.22; OS: HR = 1.64, p = 0.26). Metaplastic breast cancer samples (n = 27) demonstrated greater amount of CD163 in the stroma (p = 0.05) and PD-L1 in the tumor (p = 0.01) than triple-negative breast cancer samples (n = 119), although more triple-negative breast cancer samples were positive for CD8 in the tumor than metaplastic breast cancer samples (p = 0.02).ConclusionsPatients with metaplastic breast cancer had similar outcomes to those with triple-negative breast cancer based on DDFS and OS. The immune checkpoint marker profile of metaplastic breast cancers in this study may prove useful in future studies attempting to demonstrate an association between immune profile and survival.
Highlights
Metaplastic breast cancer (MBC) is a very rare type of invasive breast cancer in which the original cell type, usually glandular epithelium, differentiates into either epithelial and/or mesenchymal cell types with glandular and nonglandular components [1, 2]
While this may be in part due to the preponderance of the triple-negative breast cancer (TNBC) phenotype among MBCs, one prior study comparing MBC and triple-negative invasive ductal cancers showed that MBCs had worse prognosis relative to TNBCs, with shorter disease-free survival (DFS) in patients with nodal metastasis treated with adjuvant chemotherapy [10]
The Ohio State University Comprehensive Cancer Center (OSUCCC)–James Cancer Registry determined receptor status through the review of individual pathology reports utilizing the guidelines from the College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) that were available at the time of diagnosis
Summary
Metaplastic breast cancer (MBC) is a very rare type of invasive breast cancer in which the original cell type, usually glandular epithelium, differentiates into either epithelial and/or mesenchymal cell types with glandular and nonglandular components [1, 2]. An immunohistochemical panel showed that 93.8% of MBCs were basal-like, the most common subset of triple-negative breast cancer (TNBC) [5]. There is less axillary node involvement, like soft tissue sarcomas, MBCs are more prone to hematogenous dissemination and have a poor prognosis [8, 9]. While this may be in part due to the preponderance of the TNBC phenotype among MBCs, one prior study comparing MBC and triple-negative invasive ductal cancers showed that MBCs had worse prognosis relative to TNBCs, with shorter disease-free survival (DFS) in patients with nodal metastasis treated with adjuvant chemotherapy [10]. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; differences in clinical outcomes between metaplastic breast cancer and triple-negative breast cancer in the era of third-generation chemotherapy remain unclear
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
